Association of Endogenous Hormones with C-reactive Protein, Fibrinogen, and White Blood Count in Post-menopausal Women

Overview

Journal Eur J Epidemiol

Specialty Public Health

Date 2005 Dec 7

PMID 16331433

Citations 15

Authors

Aaron R Folsom

Sherita Hill Golden

Lori L Boland

Moyses Szklo

Affiliations

Soon will be listed here.

Abstract

Oral exogenous estrogen raises C-reactive protein (CRP) concentrations, but the impact of endogenous hormones is unknown. We examined the cross-sectional relation of several serum hormones with CRP, fibrinogen, and white blood cell count - three inflammatory markers linked prospectively to coronary artery disease. Serum hormones were measured on a sample (n = 317) of postmenopausal female participants, with or without carotid intima-media thickening, in the Atherosclerosis Risk in Communities (ARIC) Study. Fibrinogen and white blood cell count were available on all and CRP in a subset (n = 57). Adjusted for age, race, and case-control status, mean CRP was 2-fold greater in the highest vs. lowest quartiles of estrone and androstenedione, and CRP was 2-fold less across quartiles of sex hormone binding globulin. These associations were not all statistically significant with this sample size. Fibrinogen and white blood cell count also were associated positively with estrone, androstenedione, and testosterone (and fibrinogen also with dehydroepiandrosterone sulfate). Adjustment for other risk factors and especially body mass index, a known determinant of endogenous hormone levels, attenuated most associations. In conclusion, several endogenous sex hormones may influence basal levels of inflammatory markers. Obesity appears to play a modulating role.

Citing Articles

Sunscreen compound benzophenone-3 and its relationship with white blood cell counts.

Sadr N, Qayyum R Skin Res Technol. 2024; 30(5):e13744.

PMID: 38771547 PMC: 11107877. DOI: 10.1111/srt.13744.

D-Dimer and Fibrinogen Values according to the Localization of Deep Venous Thrombosis.

Mlaco A, Mlaco N, Begic E, Mekic M, Dzubur A Int J Angiol. 2023; 32(4):243-247.

PMID: 37927846 PMC: 10624538. DOI: 10.1055/s-0042-1759819.

Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.

Eldridge R, Wentzensen N, Pfeiffer R, Brinton L, Hartge P, Guillemette C Cancer Causes Control. 2020; 31(4):309-320.

PMID: 32100190 PMC: 7472689. DOI: 10.1007/s10552-020-01280-6.

Li T, Wang F, Peng R, Pei S, Hou Z, Lu B Biol Sex Differ. 2018; 9(1):51.

PMID: 30518417 PMC: 6282270. DOI: 10.1186/s13293-018-0210-x.

Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Roetker N, MacLehose R, Hoogeveen R, Ballantyne C, Basu S, Cushman M Thromb Haemost. 2018; 118(11):1940-1950.

PMID: 30296818 PMC: 6289254. DOI: 10.1055/s-0038-1673613.

References

Stork S, von Schacky C, Angerer P . The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis. 2002; 165(2):301-7. DOI: 10.1016/s0021-9150(02)00242-3. View

Zanger D, Yang B, Ardans J, Waclawiw M, Csako G, Wahl L . Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol. 2000; 36(6):1797-802. DOI: 10.1016/s0735-1097(00)00952-9. View

Walsh B, Paul S, Wild R, Dean R, Tracy R, Cox D . The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000; 85(1):214-8. DOI: 10.1210/jcem.85.1.6326. View

Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C . Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001; 21(2):262-8. DOI: 10.1161/01.atv.21.2.262. View

Vehkavaara S, Silveira A, Virkamaki A, Hovatta O, Hamsten A, Taskinen M . Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001; 85(4):619-25. View

. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129(4):687-702. View

Golden S, Maguire A, Ding J, Crouse J, Cauley J, Zacur H . Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002; 155(5):437-45. DOI: 10.1093/aje/155.5.437. View

Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I . Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol. 2003; 41(8):1358-63. DOI: 10.1016/s0735-1097(03)00156-6. View

Brooks-Asplund E, Tupper C, Daun J, Kenney W, Cannon J . Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine. 2002; 19(4):193-200. DOI: 10.1006/cyto.2002.1963. View

10.

Cushman M, Legault C, Barrett-Connor E, Stefanick M, Kessler C, Judd H . Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100(7):717-22. DOI: 10.1161/01.cir.100.7.717. View

11.

Oh J, Barrett-Connor E, Wedick N, Wingard D . Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002; 25(1):55-60. DOI: 10.2337/diacare.25.1.55. View

12.

Luyer M, Khosla S, Owen W, Miller V . Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab. 2001; 86(8):3629-34. DOI: 10.1210/jcem.86.8.7768. View

13.

Zegura B, Keber I, Sebestjen M, Koenig W . Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis. 2003; 168(1):123-9. DOI: 10.1016/s0021-9150(03)00088-1. View

14.

van Baal W, Kenemans P, van der Mooren M, Kessel H, Emeis J, Stehouwer C . Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999; 81(6):925-8. View

15.

Ricoux R, Pontet M, Tresca J, Engler R . [Plasma concentration of C-reactive protein in patients with high estrogen levels]. Ann Biol Clin (Paris). 1994; 52(2):125-8. View

16.

de Valk-de Roo G, Stehouwer C, Meijer P, Mijatovic V, Kluft C, Kenemans P . Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 1999; 19(12):2993-3000. DOI: 10.1161/01.atv.19.12.2993. View

17.

Folsom A, Qamhieh H, Wing R, Jeffery R, Stinson V, Kuller L . Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993; 13(2):162-9. DOI: 10.1161/01.atv.13.2.162. View

18.

Kluft C, Gevers Leuven J, Helmerhorst F, Krans H . Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2003; 39(3):149-54. DOI: 10.1016/s1537-1891(02)00304-x. View

19.

Cushman M, Costantino J, Tracy R, Song K, Buckley L, Roberts J . Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001; 21(2):255-61. DOI: 10.1161/01.atv.21.2.255. View

20.

Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires J . Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003; 107(25):3165-9. DOI: 10.1161/01.CIR.0000074208.02226.5E. View